MedTrace Logo

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

NCT01206387 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-06-05

Study results available
· View outcomes & findings →

Summary

efficacy study in patients with moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

Desoximetasone Spray 0.25%

Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days

DRUG

placebo comparator

Placebo administered to affected area twice a day for 28 days

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Novum Pharmaceutical Research Services · http://www.novumprs.com/contact

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-12-31
Completion
2011-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206387 on ClinicalTrials.gov